Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1323-1330

  Aschele, Carlo ^a   Baldo, Chiara ^a   Sobrero, Alberto F ^b   Debernardis, Domizia ^a   Bornmann, William G ^c   Bertino, Joseph R ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CYTOTOXIC AGENT; QUINAZOLINE DERIVATIVE; RALTITREXED;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; COLON CANCER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL SURVIVAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; QUINAZOLINES; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0031949701     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jackman, A. L., Farrugia, G. A., and Gibson, W. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer, 31A: 1277-1282, 1995.
2. Jackman, A. L., Taylor, G. A., and Gibson, W. ICI DI 1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
3. Liu, L. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
4. Pendyala, L., and Creaven, P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res., 53: 5970-5976, 1993.
5. Pazdur, R., and Vincent, M., for the Tomudex Colorectal Cancer Study Group. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc. Am. Soc. Chn. Oncol., 16: 801, 1997.
6. Harper, P., on behalf of the Tomudex Study Group. Advanced colorectal cancer (ACC): results from the latest Tomudex (raltitrexed) comparative study. Proc. Am. Soc. Clin. Oncol., 16: 802, 1997.
7. Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Bums, H. A., III, Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., Weiss, G. R., Elfring, G. L., Rinaldi, D. A., Schaaf, L. J., and Von-Hoff, D. D. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol., 14: 1128-1135, 1996.
8. Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., Bonneterre, J., Adenis, A., Seitz, J. F., Ganem, G., Namer, M., Conroy, T., Negrier, S., Merrouche, Y., Burki, F., Mousseau, M., Herait, P., and Mahjoubi. M. Phase II study of irinotecan in treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol., 15: 251-260, 1997.
9. Levi, F. A., Zidanil R., Vannetzel, J. M., Perpoint, B., Focan, C., Faggiuolo, R., Chollet, P., Garufi, C., Itzhaki, M., Dogliotti, L., Iacobetti, S., Adam, R., Kunstlinger, F., Gastiaburu, J., Bismuth, H., Josmin, C., and Misset, J. L. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucoverin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst., 86: 1608-1617, 1994.
10. Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., Abad, A., Francois, E., Gamelin, E., Marty, M., Sastre, J., Seitz, J. F., and Ychou, M. Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95-98, 1996.
11. de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., André, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., and Krulik, M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214-219, 1997.
12. Saltz, L. B., Kanowitz, J., Kemeny, N. E., Schaaf, L., Spriggs, D., Staton, B. A., Berkery, R., Steger, C., Eng, M., Dietz, A., Locker, P., and Kelsen, D. P. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumors. J. Clin. Oncol., 14: 2959-2967, 1996.
13. Schwartz, G. K., Kemeny, N., Saltz, L., Sugarman, A., Danso, D., Kelsen, D. K., Tong, W., and Bertino, J. Phase I trial of sequential Tomudex (TOM) and 5-fluorouracil (5FU) in patients with advanced colorectal carcinoma. Proc. Am. Soc. Clin. Oncol., 16: 728, 1997.
14. Kaneda, N., Hiroshi, N., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
15. Chou, J., and Chou, T. C. Dose Effect Analysis with Microcomputers. Cambridge, United Kingdom: Biosoft, 1987.
16. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
17. Chou, T. C. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: T. C. Chou and D. Rideout (eds.), Synergism and Antagonism in Chemotherapy, pp. 61-102. New York: Academic Press, 1991.
18. Chou, T. C., Rideout, D., and Chou, J. Chemotherapeutic synergism, potentiation and antagonism. In: R. Dulbecco (ed.), Encyclopedia of Human Biology, Vol. 2, pp. 371-379. New York: Academic Press, 1991.
19. Sobrero, A. F., and Bertino, J. R. Sequence-dependent synergism between dicloromethotrexate and cisplatin in a human colon carcinoma cell line. Cancer Treat. Rep., 69: 279-283, 1985.
20. Sobrero, A. F., Aschele, C., Guglielmi, A. P., Mori, A. M., Melioli, G. G., Rosso, R., and Bertino, J. R. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J. Natl. Cancer Inst., 85: 1937-1944, 1993.
21. Sobrero, A. F., Aschele, C., and Bertino, J. R. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol., 15: 368-381, 1997.
22. Cao, S., Frank, C., Shirasaka, T., and Rustum, Y. 5-Fluorouracil prodrugs: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin. Cancer Res., 1: 839-845, 1995.
23. Shirasaka, T., Nakano, K., Takechi, T., Satake, H., Ukida, J., Fujioka, A., Saito, H., Okabe, H., Oyama, K., Takeda, S., Unemi, N., and Fukushima, M. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxonate (S-1) against human cancer carcinoma orthotopically implanted into nude rats. Cancer Res., 56: 2602-2606, 1996.
24. McGuire, J. J., Sobrero, A., Hynes, J. B., and Bertino, J. R. Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells. Cancer Res., 47: 5975-5981, 1987.
25. Rustum, Y. M., Harstrick, A., Cao, S., Vanhoefer, U., Yin, M. B., Wilke, H., and Seeber, S. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol., 15: 389-400, 1997.
26. Pommier, Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin. Oncol., 23 (Suppl. 3): 3-10, 1996.
27. Sasaki, Y., Ohtsu, A., Shimada, Y., Ono, K., and Saijo, N. Simultaneous administration of CPT-11 and 5-fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J. Natl. Cancer Inst. 86: 1096-1098, 1994.
28. Sartorelli, A. C. Biochemical and pharmacological principles of combination chemotherapy. Biochem. Pharmacol., 23 (Suppl. 2): 129, 1974.
29. O'Reilly, S., and Rowinsky, E. C. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit. Rev. Oncol. Hematol., 24: 47-70, 1996.
30. Jodrell, D. I., Newell, D. R., Gibson, W., Hughes, L. R., and Calvert, A. H. The pharmacokinetics of the quinazoline antifolate ICI DI 1694 in mice and rats. Cancer Chemother. Pharmacol., 28: 331-338, 1991.
31. Rivory, L. P., Haaz, M., Canal, P., Lokiec, F., Armand, J., and Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials. Clin. Cancer Res., 3: 1261-1266, 1997.
32. Abigerges, D., Chabot, G. G., Armand, J., Hérait, P., Gouyette, A., and Gandia, D. Phase I trial and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol., 13: 210-221, 1995.
33. Kaneda, N., and Yokokura, T. Nonlinear pharmacokinetics of CPF-11 in rats. Cancer Res., 50; 1721-1725, 1990.
34. Zalcberg, J. R., Cunningham, D., and Van Cutsem, E. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Oncol., 14: 716-721, 1996.
35. Abigerges, D., Armand, J. P., Chabot, G. G., Da Costa, L., Fadel, E., and Cote, C. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl. Cancer Inst., 86: 446-449, 1994.